A new study published in the New England Journal of Medicine has found that people with obesity who were treated with the drug tirzepatide lost an average of 52 pounds which was an average 22.5% reduction in body weight.
Tirzepatide was recently approved by the United States Food and Drug Administration for the treatment of diabetes.
This new study tested the efficacy of Tirzepatide as a treatment for Obesity in Non-Diabetic patients.
“Obesity should be treated like any other chronic disease – with effective and safe approaches that target underlying disease mechanisms; these results underscore that tirzepatide may be doing just that.”
— Ania Jastreboff, MD, PhD
The study included 2,539 participants with obesity who were randomized to receive a placebo, tirzepatide 5 mg, tirzepatide 10mg, or tirzepatide 15 mg for 72 weeks.
The drug was primarily approved for the treatment of type 2 diabetes, but Eli Lilly, the drug trial’s sponsor, is working with the FDA on a timeline for its approval as a treatment for obesity.
The side effects of tirzepatide were primarily gastrointestinal, including nausea, vomiting, and diarrhea.
This is just one of many new pharma-based Obesity treatments that are coming soon to a pharmacist near you.
Read the Study > Medication Results in More Than 20% Weight Reduction in Individuals With Obesity
